Income Investing
Unless the situation gets dramatically worse (which we can’t completely rule out), I would argue the damage is already priced into the stock at this point. Read More
Unless the situation gets dramatically worse (which we can’t completely rule out), I would argue the damage is already priced into the stock at this point. Read More
About a year ago, I wrote about the merits of investing in what I called “the most enduring assets of all-time.” The asset? Farmland, of course. Read More
About a year ago, I wrote about the merits of investing in what I called “the most enduring assets of all-time.” The asset? Farmland, of course. Read More
Part of my mandate as Chief Investment Strategist of High-Yield Investing is to find stocks that will put more cash in your pocket. It’s that simple. And as the end of another month approaches, that means it’s time for my monthly check-in on companies that are likely to do just that… If you’re new to this, here’s how it works… In each issue of my premium newsletter, I scan the market for potential dividend hikes over the next four to six weeks. We also highlight noteworthy special distributions on the horizon. I give special attention to outsized double-digit increases and… Read More
Part of my mandate as Chief Investment Strategist of High-Yield Investing is to find stocks that will put more cash in your pocket. It’s that simple. And as the end of another month approaches, that means it’s time for my monthly check-in on companies that are likely to do just that… If you’re new to this, here’s how it works… In each issue of my premium newsletter, I scan the market for potential dividend hikes over the next four to six weeks. We also highlight noteworthy special distributions on the horizon. I give special attention to outsized double-digit increases and reliable dividend-payers that have been steadily growing payouts for a decade or more. I flag these stocks first for my premium readers. Then, I share them with the public. It’s that simple. If you’re looking for potential portfolio additions to research further, I can’t think of a better place to start. So without further delay, here’s what I’ve found this month… 3 Upcoming Dividend Hikes 1. Amgen (Nasdaq: AMGN) – Amgen is a leading global biotech developer with special expertise in cancer research and renal failure (kidney disease) treatments. Its biggest blockbuster is the anti-inflammatory drug Enbrel. This is used… Read More